<?xml version="1.0" encoding="UTF-8"?>
<p>Despite its promising results 
 <italic>in vitro, in vivo</italic> in animal models, and in compassionate-use studies in humans, remdesivir is still not approved by the FDA for use as a standard of care therapy due to lack of established data on safety and efficacy in humans. The biopharmaceutical company Giliad has initiated two phase 3 clinical trials to evaluate the safety and efficacy of this drug in COVID-19 patients.
</p>
